tamarisktechnologiesgroup.com Report : Visit Site

Technical data of the tamarisktechnologiesgroup.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host tamarisktechnologiesgroup.com. Currently, hosted in United States and its service provider is GoDaddy.com LLC .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

call us : 702.516.6451 mail us : [email protected] menu skip to content home technology about partners contact search for: developing technology for the future and delivering viable solutions today tamarisk's patented, broad-spectrum oral drug delivery system is highly resistant to gastric disentegration and significantly increases bioavailability of a given therapeutic. it can be used with both small and large molecules, including incretin-like peptides such as glp and gip discover more next generation oral drug delivery the mxba™ platform is a drug delivery technology that uses a strategic combination of natural excipients to empower novel gi transcytosis mechanisms, resulting in increased oral bioavailability. contact maximum bioavailability mxba™ the objective is not to merely enhance oral drug delivery but to tackle delivery of some of the world's most difficult apis using our patented oral drug delivery system. read more the solution for proteins, peptides, and monoclonal antibodies "the tamarisk oral drug delivery platform is a game changer." discover more announcement | delegates from tamarisk will be attending bio 2018! delegates will also be participating in the 1-on-1 partnering sessions and are quite enthusiastic to share more about our recent critical advances with the mxba technology. if you would like to schedule a meeting to learn more, please contact us today. mxba™ platform | maximum bioavailability (revised 04.29.16) oral drug delivery technology | click here press release | los angeles, april 25, 2016 oral drug delivery system | “independent rat study finds 54% oral insulin relative bioavailability using tamarisk’s mxba™ platform technology” click here or play video shareholder relations get the latest updates | click here new oral drug delivery system | tamarisk’s mxba™ platform tamarisk technologies group is an early stage drug delivery technology company with headquarters based in santa barbara, california. our patented mxba™ oral drug delivery system is a platform technology that maximizes the bioavailability of a wide range of oral drugs, including both small molecules and larger bio-molecules and bcs classes ii & iv drugs. at the core of tamarisk’s mxba™ technology is an alginate particle carrier designed to encapsulate, protect and transport payload drug candidates within the gi. unique to tamarisk are the added excipient substrates engineered into the particles to provide targeted gi delivery, added preservation and transfer of payload drugs and facilitation of novel absorption pathways. by increasing absorption and bioavailability on currently difficult to administer therapeutics, tamarisk’s mxba™ oral drug delivery system will be the next generation enabler for the pharmaceutical industry. to date, tamarisk has conducted numerous bench, cell culture, and small animal studies that confirm our particle consistently delivers significantly better than the control. in a rat study recently performed at charles river, the system was used to study the increased bioavailability of resveratrol, confirming previously observed results. however, tamarisk is now primarily focused on completing it’s work with oral protein delivery, and based on numerous studies conducted, we are confident the mxba™ oral drug delivery platform will soon be a preferred solution for use with both small and large molecules, including incretin-like peptides such as glp and gip. solving the problem because of the various challenges an orally administered drug faces on its journey through the gi, normally only a small percentage of the payload will reach the bloodstream in a desired bioactive form. this is substantially reduced when the drug’s structure is both unfamiliar and quantitatively challenging to the normal gi absorption mechanisms. these challenges require many next generation drugs, such as peptides, proteins and monoclonal antibodies, to be administered through undesirable injection technologies or in such large oral dosages that patients are exposed to a myriad of undesirable side effects. effective oral bioavailability will drive a major surge in acceptance, patient compliance and sales for these high valued drugs. tamarisk technologies is well positioned to capitalize on its disruptive broad-spectrum mxba™ platform technology to build a portfolio of drug delivery partnership opportunities with a multitude of pharmaceutical companies. products/services tamarisk has developed and patented a platform oral drug delivery system that uses a strategic combination of natural excipients to empower novel gi transcytosis mechanisms, resulting in substantially increased oral bioavailability. target markets: small molecule pharmaceuticals over-the-counter vitamins and nutraceuticals biologics (proteins/peptides, monoclonal antibodies) generics vaccines all rights reserved. unless otherwise noted, copyrights for the documents, logos, and graphic designs available on this web site are owned by tamarisk technologies group, llc. current events june 4-7, 2018 bio 2018 boston, ma tamarisk’s oral drug delivery system  tamarisk's novel, patent pending mxba™ (maximum bioavailability) delivery platform focuses on increasing the bioavailability of oral drugs. our delivery mechanism has proven effective on the span of drug formulations from small molecules to larger bio-molecules, including bcs classes ii & iv drugs. site map about contact home oral drug delivery system | mxba™ partners partners privacy tamarisk’s oral insulin delivery updates from the lab july 2018 m t w t f s s 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 copyright © tamarisk technologies group | oral drug delivery powered by wordpress , designed and developed by templatesnext menu home technology about partners contact

URL analysis for tamarisktechnologiesgroup.com

http://www.tamarisktechnologiesgroup.com/privacy/
http://www.tamarisktechnologiesgroup.com/partners-2/
http://www.tamarisktechnologiesgroup.com/updates-mxba-oral-delivery/
http://www.tamarisktechnologiesgroup.com/wp-content/uploads/2015/11/mxba-logo.jpg
http://www.tamarisktechnologiesgroup.com/contact/
http://www.tamarisktechnologiesgroup.com/#content
http://www.tamarisktechnologiesgroup.com/oral-drug-delivery-technology/
http://www.tamarisktechnologiesgroup.com/oral-insulin-delivery/
http://www.tamarisktechnologiesgroup.com/wp-content/uploads/2015/11/2page-img1.jpg
http://www.tamarisktechnologiesgroup.com/partners/
http://www.tamarisktechnologiesgroup.com/oral-drug-delivery-system/
http://www.tamarisktechnologiesgroup.com/wp-content/uploads/2015/11/tamariskbw.jpg
http://www.tamarisktechnologiesgroup.com/about/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: TAMARISKTECHNOLOGIESGROUP.COM
Registry Domain ID: 1846907820_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Updated Date: 2018-02-17T10:48:08Z
Creation Date: 2014-02-17T00:51:51Z
Registry Expiry Date: 2019-02-17T00:51:51Z
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS71.DOMAINCONTROL.COM
Name Server: NS72.DOMAINCONTROL.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-12-01T05:48:36Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR GoDaddy.com, LLC

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =tamarisktechnologiesgroup.com

  PORT 43

  TYPE domain

DOMAIN

  NAME tamarisktechnologiesgroup.com

  CHANGED 2018-02-17

  CREATED 2014-02-17

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientRenewProhibited https://icann.org/epp#clientRenewProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  NS71.DOMAINCONTROL.COM 97.74.105.46

  NS72.DOMAINCONTROL.COM 173.201.73.46

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .